Moreover, CAR T cells specific for different MM associated antigens, such as CS1 (45), B-cell maturation antigen (46), SLAMF7 (47), and CD19 (48) proved to be effective in preclinical models and/or in clinical trials. The gene discussed is CD19; the disease is Miyoshi myopathy.